ESMO Breast 2021 | ESMO Breast 2021 highlights: biomarker updates
Javier Cortés, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, shares his highlights from the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021. In particular, Dr Cortés comments on novel data on biomarkers for the prognosis and treatment of patients with breast cancer, including updates on liquid biopsy and discussions around biomarker strategy optimization. This interview took place at the virtual ESMO Breast Cancer Congress 2021
Disclosures
Javier Cortés, MD, PhD, has participated in a consulting/advisory role for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim and Kyowa Kirin; has received honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme and Daiichi Sankyo; has received institutional research funding from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C and Queen Mary University of London; holds stock, patents and intellectual property in MedSIR; and has received travel, accommodation and expenses from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo.
